Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study Journal Article
| Authors: | Foss, F.; Horwitz, S. M.; Coiffier, B.; Bartlett, N.; Popplewell, L.; Pro, B.; Pinter-Brown, L. C.; Shustov, A.; Furman, R. R.; Haioun, C.; Koutsoukos, T.; O'Connor, O. A. |
| Article Title: | Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study |
| Abstract: | Background: Transformed mycosis fungoides (tMF) is an aggressive disease, with poor prognosis and a median survival of 24 months. Patients And Methods: In the Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PROPEL) study, 12 patients with tMF were treated with a median of 10 pralatrexate doses (starting dose of 30 mg/m 2) administered weekly for 6 weeks in a 7-week cycle. The median number of prior systemic therapies was 3. Results: This retrospective analysis showed that the objective response rate in this subgroup was 25% (n = 3) per independent central review and 58% (n = 7) per investigator assessment, with this discrepancy likely attributed to challenges with photodocumentation of cutaneous lesions. The median duration of response and the median progression-free survival were 2.2 and 1.7 months, respectively, per central review, whereas median duration of response was 4.4 months, and median progression-free survival was 5.3 months per investigator assessment. Median survival was 13 months. Grade 1-3 mucositis was reported in 7 (58%) patients. Grade 4 adverse events were fatigue (n = 1) and thrombocytopenia (n = 1). Pralatrexate was well tolerated, with no toxicity-related discontinuations. Conclusions: Based on these results, pralatrexate may be a treatment option for patients with relapsed or refractory tMF. © 2012 Published by Elsevier Inc. |
| Keywords: | adult; cancer survival; clinical article; human tissue; treatment outcome; treatment response; aged; aged, 80 and over; disease-free survival; middle aged; survival analysis; retrospective studies; prednisone; drug tolerability; fatigue; review; doxorubicin; interferon; drug dose reduction; drug efficacy; drug safety; side effect; systemic therapy; alpha interferon; gemcitabine; cytarabine; rituximab; carboplatin; progression free survival; multiple cycle treatment; etoposide; mucosa inflammation; thrombocytopenia; antineoplastic combined chemotherapy protocols; recurrence; cyclophosphamide; vincristine; autologous stem cell transplantation; retrospective study; chlormethine; alanine aminotransferase; survival time; prednisolone; vorinostat; bleomycin; cancer relapse; vindesine; methylprednisolone; safety; folic acid; medical photography; folic acid antagonists; drug treatment failure; mycosis fungoides; cyclosporin; pralatrexate; aminopterin; alemtuzumab; cyanocobalamin; cladribine; efficacy; antifolate; puva; denileukin diftitox; etretin; bexarotene; psoralen; relapsed; miltefosine; refractory peripheral t-cell lymphoma; transformed mycosis fungoides |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 12 |
| Issue: | 4 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2012-08-01 |
| Start Page: | 238 |
| End Page: | 243 |
| Language: | English |
| DOI: | 10.1016/j.clml.2012.01.010 |
| PROVIDER: | scopus |
| PUBMED: | 22542448 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 September 2012" - "Source: Scopus" |
